Patents by Inventor Kenneth Charles McCullough

Kenneth Charles McCullough has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9670466
    Abstract: Replicons of pestiviruses, in particular replicons of swine fever virus, are engineered to have a defective replication thereby having lost infectivity, and further containing a foreign gene. A replicon contains all the genetic information required for its replication, but lacks essential codons or all codons of at least one of the genes encoding the viral structural proteins E1, E2, Ems or C protein, and consequently cannot generate infectious virus particles. Particular replicons are generated with a mutated gene encoding a modified Npro protein that no longer controls the cell interferon-induction pathway. Another particular replicon lacks the genes encoding all the structural proteins, the p7 protein and the NS2 protein, and has cytopathogenic properties in transduced cells. The replicons provide a new vector system that can be used for vaccination, gene delivery and gene therapy applications in mammals, including humans, as naked RNA or packaged into any form of delivery vehicle.
    Type: Grant
    Filed: December 22, 2015
    Date of Patent: June 6, 2017
    Assignee: INSTITUT FUR VIRUSKRANKHEITEN UND IMMUNPROPHYLAXE
    Inventors: Jon Duri Tratschin, Nicolas Ruggli, Kenneth Charles McCullough
  • Publication number: 20160108372
    Abstract: Replicons of pestiviruses, in particular replicons of swine fever virus, are engineered to have a defective replication thereby having lost infectivity, and further containing a foreign gene. A replicon contains all the genetic information required for its replication, but lacks essential codons or all codons of at least one of the genes encoding the viral structural proteins E1, E2, Ems or C protein, and consequently cannot generate infectious virus particles. Particular replicons are generated with a mutated gene encoding a modified Npro protein that no longer controls the cell interferon-induction pathway. Another particular replicon lacks the genes encoding all the structural proteins, the p7 protein and the NS2 protein, and has cytopathogenic properties in transduced cells. The replicons provide a new vector system that can be used for vaccination, gene delivery and gene therapy applications in mammals, including humans, as naked RNA or packaged into any form of delivery vehicle.
    Type: Application
    Filed: December 22, 2015
    Publication date: April 21, 2016
    Inventors: Jon Duri Tratschin, Nicolas Ruggli, Kenneth Charles McCullough
  • Patent number: 9249395
    Abstract: The present invention concerns replicons of pestiviruses, in particular replicons of swine fever virus, engineered to have a defective replication thereby having lost infectivity, and further containing a foreign gene. A replicon of the invention contains all the genetic information required for its replication, but lacks essential codons or all codons of at least one of the genes encoding the viral structural proteins E1, E2, Ems or C protein, and consequently cannot generate infectious virus particles. Particular replicons are generated with a mutated gene encoding a modified Npro protein that no longer controls the cell interferon-induction pathway. Another particular replicon lacks the genes encoding all the structural proteins, the p7 protein and the NS2 protein, and has cytopathogenic properties in transduced cells.
    Type: Grant
    Filed: May 30, 2009
    Date of Patent: February 2, 2016
    Assignee: INSTITUT FUR VIRUSKRANKHEITEN UND IMMUNPROPHYLAXE
    Inventors: Jon Duri Tratschin, Nicolas Ruggli, Kenneth Charles McCullough
  • Publication number: 20110244044
    Abstract: The present invention relates to a compound comprising a polyelectrolyte and, covalently linked thereto, an immunological adjuvant and/or cell targeting ligand, wherein the covalently linked entity can have both adjuvant and cell targeting characteristics. The compound is used in the preparation of hydrophilic vaccine nanoparticles, which preferably have an antigenic compound or therapeutic agent, or genetic information encoding such compounds or agents entrapped in their matrix, or covalently linked to their surfaces. Vaccine compositions comprising the particles of the invention are advantageous, because a strong and long-lasting immune response is obtained following administration of a single dose. In a preferred embodiment, the polyelectrolyte of the compound is an anionic polymer, and the particle comprises a matrix comprising chitosan.
    Type: Application
    Filed: December 9, 2009
    Publication date: October 6, 2011
    Applicant: MEDIPOL SA
    Inventors: Nathanael Rossi, Peter Kauper, Kenneth Charles McCullough, Lisa Harwood
  • Publication number: 20110189224
    Abstract: The present invention concerns replicons of pestiviruses, in particular replicons of swine fever virus, engineered to have a defective replication thereby having lost infectivity, and further containing a foreign gene. A replicon of the invention contains all the genetic information required for its replication, but lacks essential codons or all codons of at least one of the genes encoding the viral structural proteins E1, E2, Ems or C protein, and consequently cannot generate infectious virus particles. Particular replicons are generated with a mutated gene encoding a modified Npro protein that no longer controls the cell interferon-induction pathway. Another particular replicon lacks the genes encoding all the structural proteins, the p7 protein and the NS2 protein, and has cytopathogenic properties in transduced cells.
    Type: Application
    Filed: May 30, 2009
    Publication date: August 4, 2011
    Applicant: INSTITUT FUR VIRUSKRANKHEITEN UND IMMUNPROPHYLAXE
    Inventors: Jon Duri Tratschin, Nicolas Ruggli, Kenneth Charles McCullough